BeiGene (NASDAQ:BGNE – Get Free Report) and Evoke Pharma (NASDAQ:EVOK – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.
Earnings and Valuation
This table compares BeiGene and Evoke Pharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BeiGene | $2.46 billion | 8.23 | -$881.71 million | ($8.24) | -25.20 |
| Evoke Pharma | $5.18 million | 1.23 | -$7.79 million | ($10.99) | -0.39 |
Evoke Pharma has lower revenue, but higher earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Evoke Pharma, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeiGene | 0 | 2 | 6 | 0 | 2.75 |
| Evoke Pharma | 0 | 0 | 0 | 0 | 0.00 |
BeiGene currently has a consensus target price of $253.69, suggesting a potential upside of 22.19%. Given BeiGene’s stronger consensus rating and higher probable upside, equities analysts clearly believe BeiGene is more favorable than Evoke Pharma.
Profitability
This table compares BeiGene and Evoke Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeiGene | -25.94% | -25.12% | -14.95% |
| Evoke Pharma | -71.32% | -308.49% | -53.66% |
Institutional & Insider Ownership
48.6% of BeiGene shares are owned by institutional investors. 7.4% of BeiGene shares are owned by company insiders. Comparatively, 6.1% of Evoke Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
BeiGene has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500.
Summary
BeiGene beats Evoke Pharma on 12 of the 14 factors compared between the two stocks.
About BeiGene
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
About Evoke Pharma
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.
